CervoMed Patent Allowance Spurs 20% Stock Rise

CervoMed Patent Allowance Spurs 20% Stock Rise

On 18‑06‑2026 at 05:38 pm, CervoMed Inc. (NASDAQ:CRVO) reported that its shares rose approximately 20% on Thursday following a notice of allowance from the United States Patent and Trademark Office (USPTO) for a new patent. The patent protects the company’s use of neflamapimod in treating dementia with Lewy bodies (DLB).

The granted patent specifically covers treatment of DLB in patients who do not exhibit substantial Alzheimer’s disease‑like tau pathology, a condition referred to as “pure DLB.” The intellectual‑property protection is projected to extend into 2042 and may be further prolonged through patent term extension mechanisms.

CervoMed is described as a clinical‑stage biotechnology company developing therapies for age‑related brain disorders. The announcement notes that there are currently no approved treatments for DLB in either the United States or the European Union.

The article was generated with the support of artificial intelligence and subsequently reviewed by an editor, as indicated by the Reuters disclaimer.